Evidence map›Paper›PMID 40533767›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint.

Wenze Wan, Yuan Li, Wentao Sun, Zewei Cheng, Fen Ma, Sheng Shen, Houbao Liu, Jiwei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenze Wan *Department of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yuan Li *Shanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Wentao Sun *Department of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zewei ChengShanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Fen MaShanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Sheng ShenDepartment of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. shen.sheng@zs-hospital.sh.cn.
Houbao LiuDepartment of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. zsliuhb@sina.com.
Jiwei ZhangShanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. joezhang@shutcm.edu.cn.

Funding

National Natural Science Foundation of China 82272772, 81872352, 82072682, 82173106, 82130115Natural Science Foundation of Shanghai 21ZR1459100Science and Technology Commission of Shanghai Municipality 20DZ2254500Shanghai Pujiang Program 20PJ1413000
6 · The paper itself

Abstract

BACKGROUND &

aimsICC is a malignant tumor that originates from the intrahepatic bile ducts with insidious symptoms and a poor prognosis. Early diagnosis methods and therapeutic targets are urgently needed for ICC.

methodsWe utilized a comprehensive set of analytical techniques to elucidate the role and mechanisms of DCDC2 in ICC. Our study included protein microarrays, transcriptome analysis, functional assays, immunofluorescence, dual-luciferase reporter assays, as well as xenograft models and humanized PBMC models.

resultsOur study demonstrates that elevated levels of anti-DCDC2 autoantibodies in the serum of ICC patients indicate its potential utility as a diagnostic biomarker. Comprehensive in vitro and in vivo analyses reveal that DCDC2 promotes ICC proliferation, metastasis, and immune evasion. Mechanistically, DCDC2 stabilizes ENO1, resulting in enhanced AKT phosphorylation and increased expression of FGL1. Notably, elevated FGL1 levels significantly impair CD8

conclusionOur findings position anti-DCDC2 autoantibody as a promising diagnostic biomarker for ICC, associated with poor prognostic outcomes, and elucidate its critical role in tumor growth and immune evasion through its interaction with ENO1.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaDNA-Binding ProteinsMicrofilament ProteinsTumor Suppressor ProteinsAnimalsBiomarkers, TumorCell Line, TumorCell ProliferationDisease ProgressionFemaleHumansImmune EvasionLymphocyte Activation Gene 3 ProteinMaleMiceBiomarkers, TumorDNA-Binding ProteinsENO1 protein, humanLymphocyte Activation Gene 3 ProteinMicrofilament ProteinsPhosphopyruvate HydrataseTumor Suppressor ProteinsDoublecortin domain containing 2Enolase 1Fibrinogen-like protein 1Immune evasionIntrahepatic CholangiocarcinomaProgressionTumor-associated antigen

Identifiers

PMID40533767
PMCPMC12175362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.